Cepheid Boasts 35 Percent Revenue Growth for Q3 | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its third-quarter revenues rose 35 percent year over year, and the firm cut its net loss by more than two-thirds.

The Sunnyvale, Calif.-based molecular diagnostics firm brought in total revenues of $56.1 million for the three-month period ended Sept. 30, compared to $41.6 million for Q3 2009. It surpassed analysts' consensus estimate of $52.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.